Prognostic Significance of Heat Shock Protein 90 in Non Muscle Invasive Bladder Cancer Treated by BCG ImmunotherapyFaouzia Ajili1*, Amel Nedri1, Nadia Kourda2, Afifa maaloul1, salma Karay1, Amine Darouiche3, Mouhamed Chebil3 and Samir Boubaker1
- *Corresponding Author:
- Ajili Faouzia
Laboratory of Human and Experimental Pathology
Pasteur Institute of Tunis
Tunisia. Institut Pasteur de Tunis 13
Place Pasteur, 1002 Tunis, Tunisia
E-mail: [email protected]
Received Date: February 28, 2014; Accepted Date: March 20, 2014; Published Date: March 22, 2014
Citation: Ajili F, Nedri A, Kourda N, Maaloul A, Karay S, et al. (2014) Prognostic Significance of Heat Shock Protein 90 in Non Muscle Invasive Bladder Cancer Treated by BCG Immunotherapy. J Cytol Histol 5:230. doi:10.4172/2157-7099.1000230
Copyright: © 2014 Ajili F, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Background: The heat shock protein 90 (HSP90) is overexpressed and highly associated with poor prognosis in many malignancies. However, the role of HSP90 in Non muscle invasive bladder cancer (NMIBC) has not been thoroughly elucidated. The aim of this study is to investigate the relationship of HSP90 expression with the response to BCG immunotherapy of NMIBC.
Methods: HSP90 expression was evaluated by immunohistochemistry in 43NMIBC samples. The relationships between HSP90 and the response to BCG immunotherapy were analyzed. The results were correlated with clinicopathological characteristics using univariate and multivariate analyses.
Results: Univariate Cox regression analysis of baseline characteristics and HSP90 expression showed that no significant association was found with BCG immunotherapy response (p=0.894). In the other hand, multivariate Cox regression analysis showed that HSP90 protein is not an independent factor of tumor response after BCG immunotherapy (p=0.884).
Conclusion: This study demonstrates that HSP90 could not be a useful prognostic marker for BCG treatment in NMIBC. We emphasize that this was a preliminary study and therefore further confirmation on a larger set of tissues is necessary.